nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—EIF4E—cardiovascular system—nicotine dependence	0.0397	0.252	CbGeAlD
Sirolimus—Enterocolitis—Varenicline—nicotine dependence	0.0358	0.0466	CcSEcCtD
Sirolimus—Peripheral vascular disorder—Varenicline—nicotine dependence	0.0203	0.0263	CcSEcCtD
Sirolimus—EIF4E—brain—nicotine dependence	0.0195	0.124	CbGeAlD
Sirolimus—FGF2—midbrain—nicotine dependence	0.0189	0.12	CbGeAlD
Sirolimus—Urine abnormality—Varenicline—nicotine dependence	0.018	0.0233	CcSEcCtD
Sirolimus—Osteoporosis—Varenicline—nicotine dependence	0.0177	0.0231	CcSEcCtD
Sirolimus—Urine analysis abnormal—Varenicline—nicotine dependence	0.0169	0.022	CcSEcCtD
Sirolimus—MTOR—cardiovascular system—nicotine dependence	0.0154	0.0976	CbGeAlD
Sirolimus—Cyst—Varenicline—nicotine dependence	0.0149	0.0193	CcSEcCtD
Sirolimus—Menstrual disorder—Varenicline—nicotine dependence	0.0146	0.019	CcSEcCtD
Sirolimus—Thrombosis—Varenicline—nicotine dependence	0.014	0.0183	CcSEcCtD
Sirolimus—FKBP1A—cardiovascular system—nicotine dependence	0.0138	0.0878	CbGeAlD
Sirolimus—Hyperlipidaemia—Varenicline—nicotine dependence	0.0138	0.0179	CcSEcCtD
Sirolimus—Menorrhagia—Varenicline—nicotine dependence	0.0134	0.0175	CcSEcCtD
Sirolimus—Gingivitis—Varenicline—nicotine dependence	0.0127	0.0165	CcSEcCtD
Sirolimus—Glycosuria—Varenicline—nicotine dependence	0.0123	0.016	CcSEcCtD
Sirolimus—FGF2—brain—nicotine dependence	0.0119	0.0755	CbGeAlD
Sirolimus—Acne—Varenicline—nicotine dependence	0.0118	0.0154	CcSEcCtD
Sirolimus—Accidental injury—Varenicline—nicotine dependence	0.0112	0.0146	CcSEcCtD
Sirolimus—Viral infection—Varenicline—nicotine dependence	0.011	0.0143	CcSEcCtD
Sirolimus—FKBP1A—midbrain—nicotine dependence	0.0108	0.0686	CbGeAlD
Sirolimus—Nocturia—Varenicline—nicotine dependence	0.0107	0.0139	CcSEcCtD
Sirolimus—Leukocytosis—Varenicline—nicotine dependence	0.0106	0.0138	CcSEcCtD
Sirolimus—Pulmonary embolism—Varenicline—nicotine dependence	0.00994	0.0129	CcSEcCtD
Sirolimus—Eructation—Varenicline—nicotine dependence	0.00977	0.0127	CcSEcCtD
Sirolimus—Hyperkalaemia—Varenicline—nicotine dependence	0.00977	0.0127	CcSEcCtD
Sirolimus—Oesophagitis—Varenicline—nicotine dependence	0.00908	0.0118	CcSEcCtD
Sirolimus—Urine output increased—Varenicline—nicotine dependence	0.00899	0.0117	CcSEcCtD
Sirolimus—Mouth ulceration—Varenicline—nicotine dependence	0.00899	0.0117	CcSEcCtD
Sirolimus—Hypertonia—Varenicline—nicotine dependence	0.00871	0.0113	CcSEcCtD
Sirolimus—Lymphadenopathy—Varenicline—nicotine dependence	0.00846	0.011	CcSEcCtD
Sirolimus—Diabetes mellitus—Varenicline—nicotine dependence	0.0083	0.0108	CcSEcCtD
Sirolimus—Polyuria—Varenicline—nicotine dependence	0.00822	0.0107	CcSEcCtD
Sirolimus—Deafness—Varenicline—nicotine dependence	0.00807	0.0105	CcSEcCtD
Sirolimus—Injury—Varenicline—nicotine dependence	0.00785	0.0102	CcSEcCtD
Sirolimus—Increased appetite—Varenicline—nicotine dependence	0.00768	0.00998	CcSEcCtD
Sirolimus—Atrial fibrillation—Varenicline—nicotine dependence	0.00761	0.0099	CcSEcCtD
Sirolimus—MTOR—brain—nicotine dependence	0.00754	0.0479	CbGeAlD
Sirolimus—Hypoglycaemia—Varenicline—nicotine dependence	0.00739	0.00961	CcSEcCtD
Sirolimus—Osteoarthritis—Varenicline—nicotine dependence	0.00722	0.00938	CcSEcCtD
Sirolimus—Affect lability—Varenicline—nicotine dependence	0.0071	0.00923	CcSEcCtD
Sirolimus—Urinary retention—Varenicline—nicotine dependence	0.00686	0.00892	CcSEcCtD
Sirolimus—Mood swings—Varenicline—nicotine dependence	0.00684	0.00889	CcSEcCtD
Sirolimus—FKBP1A—brain—nicotine dependence	0.00678	0.0431	CbGeAlD
Sirolimus—Liver function test abnormal—Varenicline—nicotine dependence	0.00666	0.00866	CcSEcCtD
Sirolimus—Hypokalaemia—Varenicline—nicotine dependence	0.00657	0.00854	CcSEcCtD
Sirolimus—Breast disorder—Varenicline—nicotine dependence	0.00652	0.00848	CcSEcCtD
Sirolimus—Gastritis—Varenicline—nicotine dependence	0.00639	0.0083	CcSEcCtD
Sirolimus—Abdominal distension—Varenicline—nicotine dependence	0.00628	0.00816	CcSEcCtD
Sirolimus—Asthma—Varenicline—nicotine dependence	0.00624	0.00811	CcSEcCtD
Sirolimus—Dysphagia—Varenicline—nicotine dependence	0.00624	0.00811	CcSEcCtD
Sirolimus—Bronchitis—Varenicline—nicotine dependence	0.006	0.0078	CcSEcCtD
Sirolimus—CYP3A7—Xenobiotics—CYP2A7—nicotine dependence	0.00598	0.0813	CbGpPWpGaD
Sirolimus—EIF4E—Processing of Capped Intron-Containing Pre-mRNA—CCAR1—nicotine dependence	0.00587	0.0799	CbGpPWpGaD
Sirolimus—SLC47A1—brain—nicotine dependence	0.00583	0.037	CbGeAlD
Sirolimus—Pollakiuria—Varenicline—nicotine dependence	0.00576	0.00749	CcSEcCtD
Sirolimus—Erectile dysfunction—Varenicline—nicotine dependence	0.00574	0.00747	CcSEcCtD
Sirolimus—Weight increased—Varenicline—nicotine dependence	0.00568	0.00738	CcSEcCtD
Sirolimus—Hyperglycaemia—Varenicline—nicotine dependence	0.00563	0.00731	CcSEcCtD
Sirolimus—Infestation—Varenicline—nicotine dependence	0.00556	0.00723	CcSEcCtD
Sirolimus—Infestation NOS—Varenicline—nicotine dependence	0.00556	0.00723	CcSEcCtD
Sirolimus—Stomatitis—Varenicline—nicotine dependence	0.00542	0.00705	CcSEcCtD
Sirolimus—Conjunctivitis—Varenicline—nicotine dependence	0.0054	0.00703	CcSEcCtD
Sirolimus—Hepatobiliary disease—Varenicline—nicotine dependence	0.00526	0.00684	CcSEcCtD
Sirolimus—Epistaxis—Varenicline—nicotine dependence	0.00524	0.00682	CcSEcCtD
Sirolimus—Sinusitis—Varenicline—nicotine dependence	0.00522	0.00678	CcSEcCtD
Sirolimus—Hallucination—Varenicline—nicotine dependence	0.00497	0.00646	CcSEcCtD
Sirolimus—Hypoaesthesia—Varenicline—nicotine dependence	0.00497	0.00646	CcSEcCtD
Sirolimus—Urinary tract disorder—Varenicline—nicotine dependence	0.00493	0.00641	CcSEcCtD
Sirolimus—Oedema peripheral—Varenicline—nicotine dependence	0.00492	0.00639	CcSEcCtD
Sirolimus—Connective tissue disorder—Varenicline—nicotine dependence	0.00491	0.00638	CcSEcCtD
Sirolimus—Urethral disorder—Varenicline—nicotine dependence	0.00489	0.00636	CcSEcCtD
Sirolimus—Visual impairment—Varenicline—nicotine dependence	0.00481	0.00625	CcSEcCtD
Sirolimus—Tinnitus—Varenicline—nicotine dependence	0.00465	0.00605	CcSEcCtD
Sirolimus—Cardiac disorder—Varenicline—nicotine dependence	0.00463	0.00602	CcSEcCtD
Sirolimus—Angiopathy—Varenicline—nicotine dependence	0.00453	0.00589	CcSEcCtD
Sirolimus—Immune system disorder—Varenicline—nicotine dependence	0.00451	0.00586	CcSEcCtD
Sirolimus—Mediastinal disorder—Varenicline—nicotine dependence	0.0045	0.00585	CcSEcCtD
Sirolimus—Chills—Varenicline—nicotine dependence	0.00448	0.00582	CcSEcCtD
Sirolimus—Malnutrition—Varenicline—nicotine dependence	0.00435	0.00565	CcSEcCtD
Sirolimus—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00432	0.0588	CbGpPWpGaD
Sirolimus—Flatulence—Varenicline—nicotine dependence	0.00428	0.00557	CcSEcCtD
Sirolimus—Back pain—Varenicline—nicotine dependence	0.0042	0.00546	CcSEcCtD
Sirolimus—Muscle spasms—Varenicline—nicotine dependence	0.00418	0.00543	CcSEcCtD
Sirolimus—Tremor—Varenicline—nicotine dependence	0.00407	0.00529	CcSEcCtD
Sirolimus—Ill-defined disorder—Varenicline—nicotine dependence	0.00403	0.00524	CcSEcCtD
Sirolimus—Anaemia—Varenicline—nicotine dependence	0.00402	0.00522	CcSEcCtD
Sirolimus—Agitation—Varenicline—nicotine dependence	0.00399	0.00519	CcSEcCtD
Sirolimus—Angioedema—Varenicline—nicotine dependence	0.00397	0.00516	CcSEcCtD
Sirolimus—Malaise—Varenicline—nicotine dependence	0.00392	0.00509	CcSEcCtD
Sirolimus—Syncope—Varenicline—nicotine dependence	0.0039	0.00507	CcSEcCtD
Sirolimus—Palpitations—Varenicline—nicotine dependence	0.00384	0.00499	CcSEcCtD
Sirolimus—Loss of consciousness—Varenicline—nicotine dependence	0.00382	0.00497	CcSEcCtD
Sirolimus—Cough—Varenicline—nicotine dependence	0.00379	0.00493	CcSEcCtD
Sirolimus—Hypertension—Varenicline—nicotine dependence	0.00375	0.00488	CcSEcCtD
Sirolimus—Arthralgia—Varenicline—nicotine dependence	0.0037	0.00481	CcSEcCtD
Sirolimus—Chest pain—Varenicline—nicotine dependence	0.0037	0.00481	CcSEcCtD
Sirolimus—Myalgia—Varenicline—nicotine dependence	0.0037	0.00481	CcSEcCtD
Sirolimus—Anxiety—Varenicline—nicotine dependence	0.00369	0.00479	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00367	0.00478	CcSEcCtD
Sirolimus—Discomfort—Varenicline—nicotine dependence	0.00366	0.00475	CcSEcCtD
Sirolimus—Oedema—Varenicline—nicotine dependence	0.00355	0.00461	CcSEcCtD
Sirolimus—Infection—Varenicline—nicotine dependence	0.00352	0.00458	CcSEcCtD
Sirolimus—Shock—Varenicline—nicotine dependence	0.00349	0.00454	CcSEcCtD
Sirolimus—Nervous system disorder—Varenicline—nicotine dependence	0.00348	0.00452	CcSEcCtD
Sirolimus—Thrombocytopenia—Varenicline—nicotine dependence	0.00347	0.00451	CcSEcCtD
Sirolimus—Tachycardia—Varenicline—nicotine dependence	0.00346	0.0045	CcSEcCtD
Sirolimus—Skin disorder—Varenicline—nicotine dependence	0.00344	0.00448	CcSEcCtD
Sirolimus—Hyperhidrosis—Varenicline—nicotine dependence	0.00343	0.00446	CcSEcCtD
Sirolimus—Anorexia—Varenicline—nicotine dependence	0.00338	0.00439	CcSEcCtD
Sirolimus—Hypotension—Varenicline—nicotine dependence	0.00331	0.00431	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00323	0.0042	CcSEcCtD
Sirolimus—Insomnia—Varenicline—nicotine dependence	0.00321	0.00417	CcSEcCtD
Sirolimus—ABCB1—cardiovascular system—nicotine dependence	0.0032	0.0203	CbGeAlD
Sirolimus—Dyspnoea—Varenicline—nicotine dependence	0.00316	0.00411	CcSEcCtD
Sirolimus—Somnolence—Varenicline—nicotine dependence	0.00315	0.0041	CcSEcCtD
Sirolimus—Dyspepsia—Varenicline—nicotine dependence	0.00312	0.00406	CcSEcCtD
Sirolimus—Decreased appetite—Varenicline—nicotine dependence	0.00308	0.00401	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00306	0.00398	CcSEcCtD
Sirolimus—Constipation—Varenicline—nicotine dependence	0.00303	0.00394	CcSEcCtD
Sirolimus—Pain—Varenicline—nicotine dependence	0.00303	0.00394	CcSEcCtD
Sirolimus—Feeling abnormal—Varenicline—nicotine dependence	0.00292	0.0038	CcSEcCtD
Sirolimus—Gastrointestinal pain—Varenicline—nicotine dependence	0.0029	0.00377	CcSEcCtD
Sirolimus—Abdominal pain—Varenicline—nicotine dependence	0.0028	0.00364	CcSEcCtD
Sirolimus—Body temperature increased—Varenicline—nicotine dependence	0.0028	0.00364	CcSEcCtD
Sirolimus—Hypersensitivity—Varenicline—nicotine dependence	0.00261	0.0034	CcSEcCtD
Sirolimus—Asthenia—Varenicline—nicotine dependence	0.00254	0.00331	CcSEcCtD
Sirolimus—Pruritus—Varenicline—nicotine dependence	0.00251	0.00326	CcSEcCtD
Sirolimus—ABCB1—midbrain—nicotine dependence	0.0025	0.0159	CbGeAlD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00249	0.0339	CbGpPWpGaD
Sirolimus—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00248	0.0338	CbGpPWpGaD
Sirolimus—CYP3A7—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00245	0.0333	CbGpPWpGaD
Sirolimus—Diarrhoea—Varenicline—nicotine dependence	0.00243	0.00315	CcSEcCtD
Sirolimus—Dizziness—Varenicline—nicotine dependence	0.00235	0.00305	CcSEcCtD
Sirolimus—Vomiting—Varenicline—nicotine dependence	0.00225	0.00293	CcSEcCtD
Sirolimus—Rash—Varenicline—nicotine dependence	0.00224	0.00291	CcSEcCtD
Sirolimus—Dermatitis—Varenicline—nicotine dependence	0.00223	0.0029	CcSEcCtD
Sirolimus—Headache—Varenicline—nicotine dependence	0.00222	0.00289	CcSEcCtD
Sirolimus—Nausea—Varenicline—nicotine dependence	0.00211	0.00274	CcSEcCtD
Sirolimus—CYP3A7—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00201	0.0274	CbGpPWpGaD
Sirolimus—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00201	0.0273	CbGpPWpGaD
Sirolimus—MTOR—IL4-mediated signaling events—OPRM1—nicotine dependence	0.002	0.0273	CbGpPWpGaD
Sirolimus—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00179	0.0244	CbGpPWpGaD
Sirolimus—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00177	0.0241	CbGpPWpGaD
Sirolimus—ABCB1—brain—nicotine dependence	0.00157	0.00997	CbGeAlD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00155	0.0211	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00152	0.0207	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.0015	0.0204	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00149	0.0202	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—FGD1—nicotine dependence	0.00148	0.0201	CbGpPWpGaD
Sirolimus—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00145	0.0198	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.00144	0.0196	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—WASF2—nicotine dependence	0.00142	0.0193	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—WASF1—nicotine dependence	0.00136	0.0185	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00119	0.0162	CbGpPWpGaD
Sirolimus—CYP3A7—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00113	0.0154	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—CCAR1—nicotine dependence	0.00112	0.0152	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—FGD1—nicotine dependence	0.0011	0.0149	CbGpPWpGaD
Sirolimus—CYP3A7—Biological oxidations—CYP2A7—nicotine dependence	0.00107	0.0145	CbGpPWpGaD
Sirolimus—CYP3A7—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00105	0.0143	CbGpPWpGaD
Sirolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000834	0.0114	CbGpPWpGaD
Sirolimus—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000823	0.0112	CbGpPWpGaD
Sirolimus—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00082	0.0112	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.000773	0.0105	CbGpPWpGaD
Sirolimus—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000762	0.0104	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TAS2R16—nicotine dependence	0.000729	0.00991	CbGpPWpGaD
Sirolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000676	0.0092	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—FGD1—nicotine dependence	0.000572	0.00778	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—WASF2—nicotine dependence	0.00055	0.00749	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000534	0.00727	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKR1B10—nicotine dependence	0.000529	0.0072	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—WASF1—nicotine dependence	0.000528	0.00718	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—WASF2—nicotine dependence	0.000525	0.00715	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKR1B10—nicotine dependence	0.000505	0.00687	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—WASF1—nicotine dependence	0.000504	0.00685	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000425	0.00579	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FGD1—nicotine dependence	0.000419	0.00571	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TAS2R16—nicotine dependence	0.000405	0.00551	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKR1B10—nicotine dependence	0.000401	0.00545	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—WASF2—nicotine dependence	0.00039	0.0053	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000381	0.00519	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—WASF1—nicotine dependence	0.000374	0.00508	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKR1B10—nicotine dependence	0.00037	0.00504	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000359	0.00489	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—WASF2—nicotine dependence	0.000356	0.00484	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000354	0.00482	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—WASF1—nicotine dependence	0.000341	0.00464	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGD1—nicotine dependence	0.000318	0.00432	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—OPRM1—nicotine dependence	0.000307	0.00418	CbGpPWpGaD
Sirolimus—FGF2—Immune System—WASF2—nicotine dependence	0.000306	0.00416	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TAS2R16—nicotine dependence	0.000301	0.00409	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKR1B10—nicotine dependence	0.000297	0.00405	CbGpPWpGaD
Sirolimus—FGF2—Immune System—WASF1—nicotine dependence	0.000293	0.00399	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKR1B10—nicotine dependence	0.000281	0.00382	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—WASF2—nicotine dependence	0.000261	0.00355	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—WASF1—nicotine dependence	0.00025	0.0034	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGD1—nicotine dependence	0.000236	0.00321	CbGpPWpGaD
Sirolimus—MTOR—Immune System—WASF2—nicotine dependence	0.000227	0.00309	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—OPRM1—nicotine dependence	0.000225	0.00307	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—DRD2—nicotine dependence	0.000222	0.00302	CbGpPWpGaD
Sirolimus—MTOR—Immune System—WASF1—nicotine dependence	0.000218	0.00296	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000213	0.0029	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKR1B10—nicotine dependence	0.000208	0.00283	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP2A7—nicotine dependence	0.000199	0.00271	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—WASF2—nicotine dependence	0.000198	0.00269	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—WASF1—nicotine dependence	0.00019	0.00258	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP2A7—nicotine dependence	0.000183	0.00249	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—OPRM1—nicotine dependence	0.000171	0.00232	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—DRD2—nicotine dependence	0.000163	0.00222	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—WASF2—nicotine dependence	0.000147	0.002	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—WASF1—nicotine dependence	0.000141	0.00191	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000132	0.0018	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—OPRM1—nicotine dependence	0.000127	0.00172	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD2—nicotine dependence	0.000123	0.00168	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2A7—nicotine dependence	9.97e-05	0.00136	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD2—nicotine dependence	9.16e-05	0.00125	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2A7—nicotine dependence	6.14e-05	0.000836	CbGpPWpGaD
